Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data.

about

Brentuximab vedotin in CD30(+) primary cutaneous T-cell lymphomas: a review and analysis of existing data.

Item

http://www.wikidata.org/entity/Q38649847

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Brentuximab vedotin in CD30(+) ...... and analysis of existing data.

@en

type

Item

label

Brentuximab vedotin in CD30(+) ...... and analysis of existing data.

@en

prefLabel

Brentuximab vedotin in CD30(+) ...... and analysis of existing data.

@en

P1476

Brentuximab vedotin in CD30+ p ...... and analysis of existing data

@en

P2093

Heather W Wickless

http://www.w3.org/2001/XMLSchema#string

Lawrence S Feigenbaum

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma

CD30 in normal and neoplastic cells.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

WHO-EORTC classification for cutaneous lymphomas.

Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.

P304

1400-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJD.13696

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tyler H Enos

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28762479

http://www.w3.org/2001/XMLSchema#string